Gender-age-physiology stage and body mass index are useful predictors of nintedanib discontinuation and prognosis in patients with idiopathic pulmonary fibrosis and progressive fibrotic interstitial lung diseases.

ABSTRACT:

Introduction

Data on risk factors for discontinuation of nintedanib in patients with interstitial lung diseases (ILDs) are limited. The differences in tolerability between patients with idiopathic pulmonary fibrosis (IPF) and those with progressive fibrotic interstitial lung diseases (PF-ILDs), as well as between different severities, remain unclear. The aim of this study was to investigate the clinical characteristics associated with discontinuation of nintedanib, including severity and the presence of IPF or PF-ILDs, in patients with ILDs.

Methods

A multicenter, retrospective study was conducted. Patients with IPF and PF-ILDs who had been treated with nintedanib from August 2015 to December 2023 were analyzed. Severity at baseline was assessed using the gender-age-physiolo

SUBMITTER: Yazaki K 

PROVIDER: S-EPMC12751843 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature